Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06795087 · ClinicalTrials.gov registry record
Discharge Medication Use Post-Operatively in GU Cancer Patients
A clinical trial of Genitourinary Cancer, sponsored by Wake Forest University Health Sciences.
- Recruiting
- Registry status
- 684
- Enrollment target
- 1
- Study location
NCT06795087: Recruiting study of Genitourinary Cancer, sponsored by Wake Forest University Health Sciences.
NCT06795087 is a study of Genitourinary Cancer that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 684 participants, below the 1,205-participant average among 15 other Genitourinary Cancer trials with a reported enrollment target (43% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06795087, a study of Genitourinary Cancer, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.
- RECRUITING
- Registry status
- 684 participants
- Enrollment target
- 1
- Study location
Study Summary
The main purpose of this research study is to determine the amount of opioids that are taken after discharge following a cystectomy, nephrectomy (partial or total), or prostatectomy surgeries via a 30-day post- discharge opioid use and disposal survey. We will also evaluate the impact of an opioid disposal education pamphlet on proper disposal of unused opioids.
Primary Outcome
For each participant who was prescribed an opioid medication after urology surgery, the number of opioid pills consumed in 30 days after discharge will be captured as a categorical variable from the "Opioid Use and Disposal Survey". Participant-reported options include None, About one-fourth of all pills, About half of all pills, About three-fourths of all pills, or All. Participants who report that they received an opioid prescription but did not fill it will be captured as taking None.
Conditions Studied
Interventions
- OTHER Opioid Medication Disposal Education
Study Locations (1)
North Carolina
- Levine Cancer Institute - Charlotte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 684 participants |
| Start Date | 2025-02-21 |
| Est. Completion | 2027-07 |
What NCT06795087 shows while recruiting
NCT06795087 is an observational study that tracks outcomes without assigning an intervention. The registered 684 participants enrollment target is mid-sized for trials with a published cap, below the 1,205-participant average among 15 other Genitourinary Cancer trials with a reported enrollment target (43% lower).
The record links to 1 condition, with Genitourinary Cancer appearing as the primary indexed condition, and to 1 intervention - of which Opioid Medication Disposal Education is the first listed.
NCT06795087 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT06795087 about?
NCT06795087 is a clinical study titled "Discharge Medication Use Post-Operatively in GU Cancer Patients". The main purpose of this research study is to determine the amount of opioids that are taken after discharge following a cystectomy, nephrectomy (partial or total), or prostatectomy surgeries via a 30-day post- discharge opioid use and disposal survey. We will also evaluate the impact of an opioid d...
What is the current status of trial NCT06795087?
This trial is currently recruiting. The enrollment target is 684 participants. The study started on 2025-02-21. Estimated completion is 2027-07.
What conditions does trial NCT06795087 study?
This clinical trial studies the following conditions: Genitourinary Cancer.
What interventions are being tested in trial NCT06795087?
The interventions under investigation include: Opioid Medication Disposal Education (OTHER).
Who is sponsoring clinical trial NCT06795087?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06795087 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Genitourinary Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06795087's enrollment target sits among peer trials
684 4th of 15 higher than 12 of 15 other Genitourinary Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Genitourinary Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
RECRUITING
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
RECRUITING · Phase 2
-
A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies
RECRUITING
-
Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies
RECRUITING · Phase 1
-
Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05099770 · 685 participants · Phase 3
Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
- NCT05880199 · 685 participants
BSGM to Evaluate Patients With GI Symptoms
- NCT04333537 · 686 participants · Phase 2
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
- NCT06459180 · 686 participants · Phase 3
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI